CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral TabletWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)


Name (Synonyms) Correlation
drug2437 Table Setting Training Wiki 1.00
drug664 Cooking Training Wiki 1.00
drug1526 Multi-tasking Training Wiki 1.00
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D060825 Cognitive Dysfunction NIH 0.35

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0001268 Mental deterioration HPO 0.35

There is one clinical trial.

Clinical Trials


1 Randomized, Double-blind, Placebo-controlled Trial of TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)

A randomized parallel double-blinded placebo-controlled clinical trial to evaluate the effect of Emtricitabine/Tenofovir alafenamide (FTC/TAF) compared with placebo on the risk of developing SARS-CoV-2 disease (COVID-19) in healthcare workers with high transmission risk in addition to currently recommended control measures.

NCT04405271 Healthcare Workers COVID-19 SARS-CoV 2 Drug: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet Drug: Placebo

Primary Outcomes

Description: SARS-CoV-2 disease (COVID-19) with or without symptoms at week 12 of treatment as defined by the presence of specific antibodies against the virus. Positive cases will be confirmed by PCR

Measure: COVID-19 incident cases

Time: During treatment (12 weeks)

Secondary Outcomes

Description: Number of asymptomatic SARS-CoV-2 (Covid-19) infections confirmed by serology

Measure: Number of asymptomatic SARS-CoV-2 (Covid-19) infections confirmed by serology

Time: During treatment (12 weeks)

Description: Severity of symptomatic SARS-CoV-2 (Covid-19) infections as defined by the following categories: Mild symptoms: malaise, fever, cough, arthralgia myalgias, Moderate symptoms: same as above plus shortness of breath Severe symptoms: clinical status requiring admission in Intensive care unit

Measure: Severity of symptomatic COVID-19

Time: During treatment (12 weeks)

Description: Respiratory symptom duration in days

Measure: Respiratory symptom duration in days

Time: During treatment (12 weeks)

Description: Relation between treatments and symptoms duration

Measure: Relation between treatments and symptoms duration

Time: During treatment (12 weeks)

Description: Time course of specific IgM/IgG seroconversion

Measure: Time course of specific IgM/IgG seroconversion

Time: During treatment (12 weeks)


No related HPO nodes (Using clinical trials)